22nd Century Group Inc. (XXII) and AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) Comparison side by side

We are comparing 22nd Century Group Inc. (NYSEAMERICAN:XXII) and AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) on their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
22nd Century Group Inc. 25.23M 12.08 2.78M -0.03 0.00
AVEO Pharmaceuticals Inc. 4.01M 23.49 23.65M -0.20 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of 22nd Century Group Inc. and AVEO Pharmaceuticals Inc.


Table 2 represents 22nd Century Group Inc. (NYSEAMERICAN:XXII) and AVEO Pharmaceuticals Inc. (NASDAQ:AVEO)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
22nd Century Group Inc. -11.02% -3.6% -3.4%
AVEO Pharmaceuticals Inc. -589.78% 48.1% -69.9%

Risk & Volatility

22nd Century Group Inc. is 125.00% more volatile than Standard and Poor’s 500 due to its 2.25 beta. AVEO Pharmaceuticals Inc.’s 102.00% more volatile than Standard and Poor’s 500 which is a result of the 2.02 beta.


10.2 and 9.7 are the respective Current Ratio and a Quick Ratio of 22nd Century Group Inc. Its rival AVEO Pharmaceuticals Inc.’s Current and Quick Ratios are 1.1 and 1.1 respectively. 22nd Century Group Inc. has a better chance of clearing its pay short and long-term debts than AVEO Pharmaceuticals Inc.

Analyst Recommendations

In next table is given 22nd Century Group Inc. and AVEO Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
22nd Century Group Inc. 0 0 0 0.00
AVEO Pharmaceuticals Inc. 0 2 1 2.33

Competitively AVEO Pharmaceuticals Inc. has a consensus price target of $1.67, with potential upside of 184.93%.

Institutional & Insider Ownership

22nd Century Group Inc. and AVEO Pharmaceuticals Inc. has shares owned by institutional investors as follows: 29.8% and 42.2%. Insiders owned roughly 12.38% of 22nd Century Group Inc.’s shares. Comparatively, 0.3% are AVEO Pharmaceuticals Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
22nd Century Group Inc. -8.88% 3.75% 0% 24.22% 14.94% -1.07%
AVEO Pharmaceuticals Inc. -1.93% 1% -31.42% -9.38% -30.72% -27.24%

For the past year 22nd Century Group Inc. was less bearish than AVEO Pharmaceuticals Inc.


22nd Century Group Inc. beats on 8 of the 11 factors AVEO Pharmaceuticals Inc.

22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. It develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. The companyÂ’s products include RED SUN and MAGIC regular and menthol cigarettes; and SPECTRUM government research cigarettes. It is also developing X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation; and modified risk cigarettes, such as BRAND A, which has approximately 95% less nicotine than conventional tobacco cigarettes, as well as BRAND B cigarettes that contain low amount of tar per milligram of nicotine. 22nd Century Group, Inc. has a scientific collaboration with the University of Virginia; and a strategic partnership with Anandia Laboratories, Inc. The company was founded in 1998 and is headquartered in Clarence, New York.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. VincentÂ’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.